In view of the array of symptoms, the patient was referred for medical evaluation of a suspected pheochromocytoma, a neuroendocrine tumor of the adrenal gland. He underwent 24-hour blood pressure ...

adrenal incidentalomas have become an important clinical entity for which pheochromocytoma must be considered, regardless of signs and symptoms. Third, knowledge of the relationship between ...

Spear and Griswald 9 reported the first case of a fall in blood pressure after the administration of dibenamine (N, N-dibenzyl-β-chloroethylamine) to a patient who proved at operation to have a ...

The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic ...

Patients with optic disc edema are often brought to the attention of ophthalmologists either as referrals from internists or as a first consultation by a patient with visual symptoms. The ...

The supplemental new drug application is based on data from the Phase 2 LITESPARK-015 trial.

The FDA granted priority review for belzutifan for treating advanced pheochromocytoma and paraganglioma, with a PDUFA date set for May 26, 2025.

Rahway, New Jersey Tuesday, January 28, 2025, 10:00 Hrs [IST] ...

The role of chromogranin A in the assessment of surgical cure of pheochromocytoma was also investigated. The authors observed 21 consecutive patients who had pheochromocytomas at initial ...

About one-third of pheochromocytoma cases are inherited or genetic. Genetic screening can provide critical information about the patient's chance of recovery. Comprehensive screening for family ...

In a series by Petr and Else, mean age at diagnosis in this patient group ... This justifies ruling out pheochromocytoma in NF1 patients before elective surgeries under general anesthetic, as ...

The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for belzutifan for the treatment of adult and pediatric patients aged 12 years and ...